14.7  0 (0%)		04-04 16:00
Open: 14.71 High: 14.71 Volume: 2,376,385		Pre. Close: 14.7 Low: 14.7 Market Cap: 943(M)

Short term
Mid term
Targets	6-month :	17.23	1-year :	20.13
Resists	First :	14.76	Second :	17.23
Pivot price	14.66
Supports	First :	14.62	Second :	14.53
MAs	MA(5) :	14.69	MA(20) :	14.64
	MA(100) :	12.53	MA(250) :	9.46
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	70.9	D(3) :	71.2
RSI	RSI(14): 69.1
52-week	High :	14.77	Low :	6.4

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMYT ] has closed below upper band by 32.2%. Bollinger Bands are 90.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.71 - 14.78	14.78 - 14.85
Low:	14.53 - 14.61	14.61 - 14.68
Close:	14.58 - 14.7	14.7 - 14.82

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Wed, 22 Mar 2023
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici - GlobeNewswire

Thu, 12 Jan 2023
Why Shares of Amryt Pharma Jumped This Week - The Motley Fool

Mon, 09 Jan 2023
Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B - Yahoo Finance

Sun, 08 Jan 2023
Chiesi to Buy Amryt for $1.5 Billion in Rare Disease Expansion - Bloomberg

Thu, 05 Aug 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total ... - GlobeNewswire

Wed, 05 May 2021
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	64 (M)
Shares Float	37 (M)
Held by Insiders	0 (%)
Held by Institutions	77.3 (%)
Shares Short	229 (K)
Shares Short P.Month	78 (K)

EPS	0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.07
Profit Margin	-0.4 %
Operating Margin	-16.7 %
Return on Assets (ttm)	-3.2 %
Return on Equity (ttm)	-0.3 %
Qtrly Rev. Growth	8.1 %
Gross Profit (p.s.)	1.88
Sales Per Share	3.79
EBITDA (p.s.)	-1.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	108 (M)
Levered Free Cash Flow	32 (M)

PE Ratio	39.72
PEG Ratio	0
Price to Book value	2.89
Price to Sales	3.86
Price to Cash Flow	8.7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.